Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramipril for Hypertension in Children and Adolescents
NCT00389519Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of ramipril in hypertension (HTN) (4 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline to 4 Weeks in Trough Sitting Systolic Blood Pressure. Started Oct 2006; status: terminated.
02
Drugs
ramipril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00389519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389519.